Long-Acting Cabotegravir/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report

被引：3
|
作者：
Sunagawa, Shawnalyn W. [1 ,3 ]
Havens, Joshua P. [1 ,2 ]
Podany, Anthony [1 ]
Walker, Bryan [2 ]
Scarsi, Kimberly K. [1 ,2 ]
Bares, Sara H. [2 ]
机构：
[1] Univ Nebraska Med Ctr, Coll Pharm, Omaha, NE 68198 USA
[2] Univ Nebraska Med Ctr, Coll Med, Dept Internal Med, Div Infect Dis, Omaha, NE 68198 USA
[3] Univ Nebraska Med Ctr, Dept Pharm Practice & Sci, 986145 Nebraska Med Ctr, Omaha, NE 68198 USA
来源：
OPEN FORUM INFECTIOUS DISEASES | 2023年 / 10卷 / 12期
关键词：
drug-drug interactions; long-acting cabotegravir/rilpivirine; plasma concentrations; rifamycins;
D O I：
10.1093/ofid/ofad604
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
As antiretroviral therapy advancements focus on long-acting medications, there is a need to assess the potential impact of drug-drug interactions. We present a real-world case of long-acting cabotegravir/rilpivirine co-administered with intravenous rifampin. The combination resulted in both cabotegravir and rilpivirine concentrations falling below 4 times the protein-adjusted IC90.
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 infection switching to long-acting cabotegravir and rilpivirine
    Rubenstein, E.
    Diemer, M.
    Goldwirt, L.
    Lascoux-Combe, C.
    Lafaurie, M.
    Ponscarme, D.
    Denis, B.
    De Castro, N.
    Rami, A.
    Sellier, P. -O.
    Deville, L.
    Chaix, M. -L.
    Delaugerre, C.
    Molina, J. -M.
    HIV MEDICINE, 2023, 24 : 481 - 482
  • [32] Is Nonsustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Really Independent of Drug Levels?
    Thoueille, Paul
    Marzolini, Catia
    Guidi, Monia
    Cavassini, Matthias
    Decosterd, Laurent A.
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [33] Acceptability of Long-Acting Cabotegravir plus Rilpivirine in a Large, Urban, Ambulatory HIV Clinic
    Luc, Casey Morgan
    Max, Blake
    Perez, Sarah
    Herrera, Kara
    Huhn, Gregory
    Dworkin, Mark S.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 97 (04) : 409 - 415
  • [34] Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong
    Chan, M. C. J.
    Chik, S. H. T.
    Lamb, S. S.
    Choi, Y. C. C.
    Lau, W. T. A.
    Leung, C. S. E.
    To, P. Y. L.
    Lau, P. L. D.
    Tsang, T. Y. O.
    HIV MEDICINE, 2023, 24 : 155 - 156
  • [35] Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy
    Atoyebi, Shakir
    Bunglawala, Fazila
    Cottura, Nicolas
    Granana-Castillo, Sandra
    Montanha, Maiara Camotti
    Olagunju, Adeniyi
    Siccardi, Marco
    Waitt, Catriona
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [36] Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
    Orkin, Chloe O. C.
    Arasteh, Keikawus A. K.
    Hernandez-Mora, M. Gorgolas M. G. H. M.
    Pokrovsky, Vadim P. V.
    Overton, Edgar T. O. E. T.
    Girard, Pierre-Marie G. P. M.
    Oka, Shinichi O. S.
    Walmsley, Sharon W. S.
    Bettacchi, Chris B. C.
    Brinson, Cynthia B. C.
    Philibert, Patrick P. P.
    Lombaard, Johan L. J.
    Clair, Marty C. M.
    Crauwels, Herta C. H.
    Ford, Susan L. F. S. L.
    Patel, Parul P. P.
    Chounta, Vasiliki C. V.
    D'Amico, Ronald D. R.
    Vanveggel, Simon V. S.
    Dorey, David D. D.
    Cutrell, Amy C. A.
    Griffith, Sandy G. S.
    Margolis, David A. M. D. A.
    Williams, Peter E. W. P. E.
    Parys, Wim P. W.
    Smith, Kimberly Y. S. K. Y.
    Spreen, William R. S. W. R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1124 - 1135
  • [37] Use of long-acting cabotegravir plus rilpivirine during hemodialysis and solid organ transplantation
    Rezzonico, Leonardo F.
    Baldassari, Luca
    Peracchi, Francesco
    Merli, Marco
    Puoti, Massimo
    Rossotti, Roberto
    AIDS, 2023, 37 (09) : 1491 - 1493
  • [38] A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
    Bares, Sara H.
    Scarsi, Kimberly K.
    CURRENT OPINION IN HIV AND AIDS, 2022, 17 (01) : 22 - 31
  • [39] Efficacy and safety of long-acting intramuscular cabotegravir and rilpivirine in women: a substudy of the RELATIVITY cohort
    Galindo Puerto, Maria Jose
    Cabello Clotet, Noemi
    Aldamiz-Echevarria Lois, Teresa
    Llenas-Garcia, Jara
    Mar Arcos, Mari
    Troya, Jesus
    Buzon Martin, Luis
    Torralba, Miguel
    Santacreu, Mireia
    Aguilera Garcia, Maria
    Cabello Ubeda, Alfonso
    Crusells-Canales, Maria Jose
    Morano, Luis
    Pedrero Tome, Roberto
    Martin Rico, Patricia
    Montero Hernandez, Carmen
    Perez Martinez, Desiree
    de la Fuente Moral, Sara
    Calderon Hernaiz, Ruth
    Bernal, Enrique
    Vivancos Gallego, Maria Jesus
    Antonia Sepulveda, Maria
    Cecilio, Alvaro
    Arenas Garcia, Victor
    Padilla, Sergio
    Losa Garcia, Juan Emilio
    de las Revillas Almajano, Francisco Arnaiz
    Sanchez Guirao, Antonio Jesus
    Garcia Navarro, Maria Del Mar
    Cerezales Calvino, Ana
    Garcinuno Jimenez, Maria Angeles
    Ferreira Pasos, Eva Maria
    Estebanez, Miriam
    De la Calle Riaguas, Beatriz
    Egido Murciano, Miguel
    Ramos Vicente, Noemi
    Clavero Olmos, Marta
    Manuel Tiraboschi, Juan
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 75 - 76
  • [40] The use and utility of toolkits in supporting cabotegravir plus rilpivirine long-acting implementation in the CARISEL (Cabotegravir And Rilpivirine Implementation Study in European Locations) study
    Trehan, Rekha
    Gutner, Cassidy
    Okoli, Chinyere
    Ghosn, Jade
    Vera, Francisco
    Florence, Eric
    Lutz, Thomas
    van der Valk, Marc
    Czarnogorski, Maggie
    HIV MEDICINE, 2023, 24 : 93 - 93
12345